Læknablaðið - 15.12.1987, Blaðsíða 14

426
LÆKNABLAÐIÐ
8. Johns DW, Baker KM, Ayers CR, Vaughan ED,
Carey RM, Peach MJ, Yancey MS, et al. Acute and
chronic effect of captopril in hypertensive patients.
Hypertension 1980; 2: 567-75.
9. Waeber B, Gavras I, Brunner HR, Cook CA,
Charocopos F, Gavras HP. Prediction of sustained
antihypertensive efficacy of chronic captopril
therapy: Relationships to immediate blood pressure
response and control plasma renin activity. Am
Heart J 1982; 103 (3); 384-90.
10. Laragh JH, Case DB, Atlas SA, Sealey JE.
Captopril compared with other antirenin system
agents in hypertensive patients: Its triphasic
effects on blood pressure and its use to identify and
treat the renin factor. Hypertension 1980; 2: 586-93.
11. VA Study Group. Low-dose captopril for the
treatment of mild to moderate hypertension. Arch
Intern Med 1984; 144: 1947-53.
12. Captopril Research Group of Japan. Clinical
effects of low-dose captopril plus a thiazide diuretic
on mild to moderate essential hypertension: A
multicenter double-blind comparison with
propranolol. J Cardiovasc Pharmacol 1985; 7 (2):
77-81.
13. Maruyama A, Ogihara T, Naka T, Mikami H, Hata
T, Nakamaru M, Iwanaga K, et al. Long-term
effects of captopril in hypertension. Clin
Pharmacol Ther 1980; 28: 316-23.
14. Rasmussen S, Leth A, Ibsen H, Nielsen MD,
Nielsen F, Giese J. Converting enzyme inhibition in
mild and moderate essential hypertension. Acta
Med Scand 1985; 218: 435-42.
15. Hricik DE, Browning PJ, Kopelman R, Goorno
WE, Madias NE, Dzau VJ. Captopril-induced
functional renal insufficiency in patients with
bilateral renal-artery stenoses or renal-artery
stenosis in a solitary kidney. N Engl J Med 1983;
308: 373-6.
16. Waeber B, Brunner HR, Brunner DB, Curtet AL,
Turini GA, Gavras H. Discrepancy between
antihypertensive effect and angiotensin converting
enzyme inhibition by captopril. Hypertension 1980;
2: 236-42.
17. Medical Research Council Working Party on Mild
to Moderate Hypertension. Adverse reactions to
bendrofluazide and propranolol for the treatment
of mild hypertension. Lancet 1981; ii: 539-43.
18. Weinberger MH. Influence of an angiotensin
converting-enzyme inhibition on diuretic-induced
metabolic effects in hypertension. Hypertension
1983; 5 (3): 132-8.
19. Santucci A, Aguglia F, de Mattia G, Ficara C,
Balsano F. Long-term captopril treatment in
moderate to severe hypertension. Br J Clin
Pharmacol 1982; 14 (2): 77-9.
20. Grantz FR, Swartz SL, Hollenberg NK, Moore TJ,
Dluhy RG, Levine L, Williams GH. Role of
prostaglandins in the hypotensive response to
captopril in essential hypertension. Clin Research
1979; 27: 592A.
21. Ogihara T, Maruyama A, Hata T, Mikami H,
Nakamaru M, Naka T, Ohde H, et al. Hormonal
responses to long-term converting enzyme
inhibition in hypertensive patients. Clin Pharmacol
Ther 1981; 30: 328-35.
22. Puddey IB, Beilin LJ, Vandongen R, Banks R,
Rouse I. Differential effects of sulindac and
indomethacin on blood pressure in treated essential
hypertensive subjects. Clin Science 1985; 69:
327-36.
23. Oliver JA, Sciacca RR, Eng SD, Cannon PJ. Renal
vasodilatation by converting enzyme inhibition.
Role of renal prostaglandins. Hypertension 1983;
5:166-71.
24. Ciabattoni G, Cinotti GA, Pierucci A, Simonetti
BM, Manzi M, Pugliese F, Barsotti P, et al. Effects
of sulindac and ibuprofen in patients with chronic
glomerular disease. Evidence for the dependence of
renal function on prostacyclin. N Engl J Med 1984;
310: 279-83.
25. Clive DM, Stoff JS. Renal syndromes associated
with nonsteroidal antiinflammatory drugs. N Engl
J Med 1984; 310: 363-72.
26. Textor SC, Bravo EL, Fouad FM, Tarazi RC.
Hyperkalemia in azotemic patients during
angiotensin-converting enzyme inhibition and
aldosterone reduction with captopril. Am J Med
1982; 73: 719-25.